A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia.

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Ceftaroline fosamil (Primary) ; Ceftriaxone; Clarithromycin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms FOCUS-1; FOCUS-I
  • Sponsors Cerexa
  • Most Recent Events

    • 05 Jun 2017 Results of subgroup analysis from two phase III studies (FOCUS-1 and FOCUS-2) presented at the ASM Microbe 2017.
    • 12 Apr 2016 Results from CANVAS-1, CANVAS 2, COVERS, FOCUS 1, FOCUS 2 and Asia CAP trials (n=4055) presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
    • 01 Nov 2010 The FDA has approved ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia based on results from this study, according to a Forest media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top